KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $1.6 million.

  • Travere Therapeutics' Cost of Revenue fell 252.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 597.64%. This contributed to the annual value of $7.7 million for FY2024, which is 3236.68% down from last year.
  • Latest data reveals that Travere Therapeutics reported Cost of Revenue of $1.6 million as of Q3 2025, which was down 252.15% from $1.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Cost of Revenue high stood at $4.7 million for Q1 2025, and its period low was -$1.1 million during Q4 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $1.6 million (2024), whereas its average is $1.9 million.
  • In the last 5 years, Travere Therapeutics' Cost of Revenue tumbled by 15164.09% in 2021 and then surged by 42580.65% in 2023.
  • Travere Therapeutics' Cost of Revenue (Quarter) stood at -$1.1 million in 2021, then skyrocketed by 181.12% to $868000.0 in 2022, then soared by 425.81% to $4.6 million in 2023, then crashed by 44.06% to $2.6 million in 2024, then tumbled by 37.92% to $1.6 million in 2025.
  • Its Cost of Revenue stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $4.7 million for Q1 2025.